Showing 7251-7260 of 10469 results for "".
- Almirall Acquires Veltin® and Altabax® from Stiefel, a GSK Companyhttps://practicaldermatology.com/news/almirall-acquires-veltin-and-altabax-from-stiefel-a-gsk-company/2458802/Almirall has acquired the rights to Veltin® and Altabax, from Stiefel, a GSK company, in exchange for distribution rights to Toctino® and an undisclosed cash payment.
- ASDSA Patient Safety Hero Honorees Recognizedhttps://practicaldermatology.com/news/asdsa-patient-safety-hero-honorees-recognized/2458810/The American Society for Dermatologic Surgery Association (ASDS) announced its Patient Safety Hero Award recipients during the recent 2015 ASDS Annual Meeting in Chicago to recognize leaders who have taken an active role in the promotion and protection of patient safety in dermatologic procedures
- American Skin Association Medical Advisory Committee Names New Co-Chairhttps://practicaldermatology.com/news/american-skin-association-medical-advisory-committee-names-new-co-chair/2458807/American Skin Association (ASA) named current member Robert Modlin, MD as Co-Chair of its Medical Advisory Committee (MAC) alongside Dr. David Norris. Dr. Modlin is Chief of the Division of Dermatology and Professor of Dermatology in the Department of Medicine and Department of Microbiology, Immu
- GSK: Positive Phase 3 Results for Benlysta® In Patients with Systemic Lupus Erythematosushttps://practicaldermatology.com/news/gsk-positive-results-phase-3-results-for-benlysta-in-patients-systemic-lupus-erythematosus/2458812/Results from the BLISS-SC Phase 3 pivotal study in patients with active, autoantibody-positive systemic lupus erythematosus (SLE) show that Benlysta®(belimumab) 200mg administered weekly via subcutaneous injection plus
- Provectus Biopharmaceuticals: Immune Mechanism of Action Data for PV-10 Presented at Society for Immunotherapy of Cancer Annual Meetinghttps://practicaldermatology.com/news/provectus-biopharmaceuticals-immune-mechanism-of-action-data-for-pv-10-presented-at-society-for-immunotherapy-of-cancer-annual-meeting/2458823/Researchers from Moffitt Cancer Center in Tampa, FL, presented a poster titled, “Intralesional Rose Bengal in Melanoma Elicits Tumor Immunity via High Mobility Group Box 1,” at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting in National Harbor, MD, accor
- Research Shows Skin Can Reflect Eating Habitshttps://practicaldermatology.com/news/research-shows-skin-can-reflect-eating-habits/2458822/Dermatologists at Baylor College of Medicine say there is evidence that links certain foods to flares in acne. “While there are definitely a number of triggers for acne, the connection between diet and acne is very interesting,” said Dr. Rajani Katta, professor of dermatology
- Revision Skincare Announces Partnership with World Champion Gymnast Aly Raismanhttps://practicaldermatology.com/news/revision-skincare-announces-partnership-with-world-champion-gymnast-aly-raisman/2458824/World Champion gymnast and three-time Olympic gold medalist Aly Raisman is now an ambassador for the Revision Skincare brand. “My partnership with Revision Skincare is very important to me because I used to struggle with skin problems before using their products,” Ms. Raisman
- Dr. Mandy Honored with ASDS Stegman Awardhttps://practicaldermatology.com/news/dr-mandy-honored-with-asds-stegman-award/2458828/Stephen H. Mandy, M.D., of Miami Beach, FL, was presented recently with the Samuel J. Stegman, MD, Award for Distinguished Service, the highest honor bestowed by the American Society for Dermatologic Surgery (ASDS). The Stegman Award – given to Dr. Mandy during the 2015 ASDS Annual
- Revance Reports Positive 6-Month Duration for RT002 in BELMONT Studyhttps://practicaldermatology.com/news/revance-reports-positive-6-month-duration-for-rt002-in-belmont-study/2458831/Revance Therapeutics, Inc., shared positive 24-week results from its multi-center BELMONT Phase 2 active comparator study of injectable RT002. The ongoing study for the treatment of glabellar lines in 268 subjects compared the safety, efficacy, and duration of effect of three doses of RT002
- SecurityMetrics: HIPAA Report Reveals Healthcare's Shortcomingshttps://practicaldermatology.com/news/hipaa-report-reveals-healthcares-shortcomings/2458840/A significant security disparity exists among healthcare c-suite and IT departments, outlined by the SecurityMetrics HIPAA Security Rule Report. In a survey of c-level, risk officers, and IT managers, a 10-20% gap was revealed between what executives believe is happening in regards to patient dat